Is LNTH or CMPS more profitable?

Lantheus has a net margin of 17.69% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Compass Pathways N/A -49.63% -13.08%

Does the media favor LNTH or CMPS?

In the previous week, Lantheus had 3 more articles in the media than Compass Pathways. MarketBeat recorded 10 mentions for Lantheus and 7 mentions for Compass Pathways. Lantheus' average media sentiment score of 1.33 beat Compass Pathways' score of 1.15 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CMPS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is CMPS or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Belite Bio N/A -11.84% -11.62%

Does the media refer more to CMPS or BLTE?

In the previous week, Compass Pathways had 5 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Compass Pathways and 2 mentions for Belite Bio. Compass Pathways' average media sentiment score of 1.15 beat Belite Bio's score of 0.93 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LQDA or CMPS more profitable?

Liquidia has a net margin of 30.74% compared to Compass Pathways' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% Compass Pathways N/A -49.63% -13.08%

Does the media prefer LQDA or CMPS?

In the previous week, Liquidia and Liquidia both had 7 articles in the media. Compass Pathways' average media sentiment score of 1.15 beat Liquidia's score of 0.86 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, DFTX or CMPS?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is DFTX or CMPS more profitable?

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Compass Pathways N/A -49.63% -13.08%

Does the media refer more to DFTX or CMPS?

In the previous week, Compass Pathways had 2 more articles in the media than Definium Therapeutics. MarketBeat recorded 7 mentions for Compass Pathways and 5 mentions for Definium Therapeutics. Compass Pathways' average media sentiment score of 1.15 beat Definium Therapeutics' score of 0.91 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CMPS or AMRX?

In the previous week, Compass Pathways had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for Compass Pathways and 6 mentions for Amneal Pharmaceuticals. Compass Pathways' average media sentiment score of 1.15 beat Amneal Pharmaceuticals' score of 0.71 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Compass Pathways (CMPS) Competitors

$13.73 -0.91 (-6.22%)

As of 08/28/2026 04:00 PM Eastern

Compare

CMPS vs. LNTH, BLTE, LQDA, DFTX, and AMRX

Should you buy Compass Pathways stock or one of its competitors? Compass Pathways's main competitors and comparable companies include Lantheus (LNTH), Belite Bio (BLTE), Liquidia (LQDA), Definium Therapeutics (DFTX), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Compass Pathways compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Lantheus presently has a consensus target price of $108.11, indicating a potential upside of 7.29%. Compass Pathways has a consensus target price of $23.36, indicating a potential upside of 70.12%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

In the previous week, Lantheus had 3 more articles in the media than Compass Pathways. MarketBeat recorded 10 mentions for Lantheus and 7 mentions for Compass Pathways. Lantheus' average media sentiment score of 1.33 beat Compass Pathways' score of 1.15 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Compass Pathways	N/A	-49.63%	-13.08%

Lantheus has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.34
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Summary

Lantheus beats Compass Pathways on 10 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Belite Bio?

Compass Pathways (NASDAQ:CMPS) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Belite Bio's return on equity of -11.84% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Belite Bio	N/A	-11.84%	-11.62%

Compass Pathways currently has a consensus price target of $23.36, suggesting a potential upside of 70.12%. Belite Bio has a consensus price target of $205.80, suggesting a potential upside of 35.64%. Given Compass Pathways' stronger consensus rating and higher possible upside, equities research analysts plainly believe Compass Pathways is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Compass Pathways had 5 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Compass Pathways and 2 mentions for Belite Bio. Compass Pathways' average media sentiment score of 1.15 beat Belite Bio's score of 0.93 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market.

Belite Bio is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

Compass Pathways beats Belite Bio on 9 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Liquidia presently has a consensus price target of $98.08, indicating a potential upside of 44.90%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 70.12%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

64.5% of Liquidia shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Liquidia has a net margin of 30.74% compared to Compass Pathways' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Compass Pathways	N/A	-49.63%	-13.08%

Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

In the previous week, Liquidia and Liquidia both had 7 articles in the media. Compass Pathways' average media sentiment score of 1.15 beat Liquidia's score of 0.86 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$450.91M	13.44	-$68.92M	$1.37	49.41
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Summary

Liquidia beats Compass Pathways on 9 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Definium Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 53.73%. Compass Pathways has a consensus target price of $23.36, indicating a potential upside of 70.12%. Given Compass Pathways' higher probable upside, analysts plainly believe Compass Pathways is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Compass Pathways had 2 more articles in the media than Definium Therapeutics. MarketBeat recorded 7 mentions for Compass Pathways and 5 mentions for Definium Therapeutics. Compass Pathways' average media sentiment score of 1.15 beat Definium Therapeutics' score of 0.91 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Compass Pathways	N/A	-49.63%	-13.08%

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Summary

Compass Pathways beats Definium Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Amneal Pharmaceuticals?

Compass Pathways (NASDAQ:CMPS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Amneal Pharmaceuticals has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80

Compass Pathways has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Compass Pathways' net margin of 0.00%. Compass Pathways' return on equity of -49.63% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

In the previous week, Compass Pathways had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for Compass Pathways and 6 mentions for Amneal Pharmaceuticals. Compass Pathways' average media sentiment score of 1.15 beat Amneal Pharmaceuticals' score of 0.71 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways presently has a consensus target price of $23.36, suggesting a potential upside of 70.12%. Amneal Pharmaceuticals has a consensus target price of $19.00, suggesting a potential upside of 8.32%. Given Compass Pathways' higher probable upside, analysts plainly believe Compass Pathways is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Summary

Amneal Pharmaceuticals beats Compass Pathways on 8 of the 15 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.90B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-2.97	787.65	273.16	25.45
Price / Sales	N/A	792.89	605.00	76.62
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	22.51	11.97	12.98	6.14
Net Income	-$287.86M	$2.83B	$3.48B	$348.86M
7 Day Performance	3.00%	0.39%	0.13%	-0.80%
1 Month Performance	18.67%	5.34%	7.08%	4.13%
1 Year Performance	210.63%	6.05%	24.67%	15.17%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	2.5615 of 5 stars	$13.73 -6.2%	$23.36 +70.1%	+210.6%	$1.90B	N/A	N/A	120	Positive News Options Volume
LNTH Lantheus	3.9512 of 5 stars	$100.80 +0.8%	$108.11 +7.3%	+83.6%	$6.53B	$1.54B	24.35	1,193	Positive News Analyst Upgrade
BLTE Belite Bio	3.1516 of 5 stars	$158.87 -1.4%	$205.80 +29.5%	+140.7%	$6.46B	N/A	N/A	10
LQDA Liquidia	4.1956 of 5 stars	$70.27 +2.4%	$98.08 +39.6%	+144.5%	$6.14B	$158.32M	51.29	50	Insider Trade
DFTX Definium Therapeutics	3.7456 of 5 stars	$43.27 -3.7%	$63.00 +45.6%	+361.5%	$6.03B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. LNTH, BLTE, LQDA, DFTX, and AMRX

How does Compass Pathways compare to Lantheus?

Summary

How does Compass Pathways compare to Belite Bio?

Summary

How does Compass Pathways compare to Liquidia?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Summary

How does Compass Pathways compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. LNTH, BLTE, LQDA, DFTX, and AMRX

How does Compass Pathways compare to Lantheus?

Do analysts recommend LNTH or CMPS?

Do insiders & institutionals believe in LNTH or CMPS?

Which has more volatility & risk, LNTH or CMPS?

Does the media favor LNTH or CMPS?

Is LNTH or CMPS more profitable?

Which has preferable earnings and valuation, LNTH or CMPS?

Summary

How does Compass Pathways compare to Belite Bio?

Is CMPS or BLTE more profitable?

Do analysts rate CMPS or BLTE?

Do insiders and institutionals believe in CMPS or BLTE?

Does the media refer more to CMPS or BLTE?

Which has more volatility & risk, CMPS or BLTE?

Which has preferable valuation & earnings, CMPS or BLTE?

Summary

How does Compass Pathways compare to Liquidia?

Do analysts prefer LQDA or CMPS?

Do institutionals and insiders believe in LQDA or CMPS?

Is LQDA or CMPS more profitable?

Which has more risk and volatility, LQDA or CMPS?

Does the media prefer LQDA or CMPS?

Which has preferable earnings and valuation, LQDA or CMPS?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Which has more volatility & risk, DFTX or CMPS?

Do insiders & institutionals have more ownership in DFTX or CMPS?

Do analysts prefer DFTX or CMPS?

Does the media refer more to DFTX or CMPS?

Is DFTX or CMPS more profitable?

Which has stronger valuation & earnings, DFTX or CMPS?

Summary

How does Compass Pathways compare to Amneal Pharmaceuticals?

Which has preferable valuation and earnings, CMPS or AMRX?

Which has more volatility & risk, CMPS or AMRX?

Do institutionals & insiders hold more shares of CMPS or AMRX?

Is CMPS or AMRX more profitable?

Does the media favor CMPS or AMRX?

Do analysts prefer CMPS or AMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools